ClinicalTrials.gg
RecruitingNCT06870006Updated Mar 18, 2026

Psychotropic-Drug-induced QT Prolongation and ECG Monitoring in the Pediatric Population

An observational study in Eating Disorders, Mood Disorders in Children and Adolescents and Psychotic Disorder, sponsored by Meyer Children's Hospital IRCCS. Recruiting at 6 sites in Italy. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Meyer Children's Hospital IRCCS · Observational

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
Up to 18 Years
Sex
All
01

Study summary

Electrocardiogram (ECG) Q-T prolongation is a cardiac electrophysiological disorder associated with the occurrence of arrhythmias potentially fatal. Several psychotropic drugs are associated with an increased risk of QT prolongation, which is why in clinical practice a baseline ECG is performed before a psychotropic drug is prescribed. However, there are no validated protocols establishing when to repeat this examination or describing clinical events when this examination should be repeated in clinical follow-up.

The study aims to investigate the incidence of QTc prolongation events as a side effect of chronic psychotropic drug administration. For this purpose, ECGs will be recorded and confounding factors of patients at the beginning of psychotropic therapy and after 3, 6 and 12 months will be analyzed.

02

Conditions studied

  • Eating Disorders
  • Mood Disorders in Children and Adolescents
  • Psychotic Disorder
  • QTc Intervals Changes

Keywords

  • QTc interval
  • psychotropic drugs
03

In context

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 153 are open to participants now.

This study's planned enrollment of 100 is close to the median of 102 across 177 observational studies indexed under Feeding and Eating Disorders.

Browse Feeding and Eating Disorders studies →

Lead sponsor

Meyer Children's Hospital IRCCS is the lead sponsor of 78 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children and adolescents referring to psychiatry services in one the participating hospitals starting a new prescription for a psychotropic drug acting on QT interval.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Admitted to psychiatry ward
  • Starting a psychotropic drug acting on

Exclusion criteria

Exclusion Criteria:

  • Age >18aa
  • History of administration of drug acting on in the 3 months prior
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Monotherapy

    Patients taking only one drug acting on QT interval

  • Monotherapy to monotherapy

    Patients who have switched from a drug acting on QT interval to another

  • Polytherapy

    Patients taking more than one drug acting on QT interval

06

What researchers measure

Primary outcomes

  1. Changes in QT interval

    Time frame: Baseline, 1, 3, 6, 12, 18 months post- enrollment

Secondary outcomes

  1. Number of Cardiac events

    Time frame: Baseline, 1, 3, 6, 12, 18 months post- enrollment

07

Study locations

2 of 6 sites recruiting
  • Neuropsichiatria Infantile, IRCCS - OC Associazione Oasi Maria SS. ONLUS
    Troina, Enna 94018, Italy
    Not yet recruiting
  • AOU Meyer IRCCS
    Florence, FI 50139, Italy
    Recruiting
  • IRCCS Fondazione Stella Maris
    Calambrone, Pisa 56128, Italy
    Recruiting
  • Neuropsichiatria infantile, Policlinico S.Orsola-Malpighi
    Bologna, 40138, Italy
    Active, not recruiting

    Not enrolling at this site.

  • Clinica di Neuropsichiatria dell'Infanzia e dell'adolescenza, Ospedale Pediatrico A. Cao ARNAS G. Brotzu
    Cagliari, 09121, Italy
    Not yet recruiting
  • Neuropsichiatria Infantile, Azienda Ospedaliera-Universitaria "Gaetano Martino"
    Messina, 98124, Italy
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06870006
Lead sponsor
Meyer Children's Hospital IRCCS
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Jan 1, 2024
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

Tiziana Pisano, MD
Contact
tiziana.pisano@meyer.it
3498705830 ext. +39

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion